Hinge Health (HNGE) EBITDA (2024 - 2026)

Hinge Health (HNGE) has 3 years of EBITDA data on file, last reported at $32.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 144.11% year-over-year to $32.1 million; the trailing twelve-month figure through Mar 2026 stood at -$527.4 million (down 4269.15% YoY), and the FY2025 full-year result was -$546.4 million, down 1612.23% from the prior year.
• EBITDA grew to $32.1 million in Q1 2026, from $27.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $32.1 million in Q1 2026 to a low of -$580.7 million in Q2 2025.
• A 3-year average of -$64.3 million and a median of $4.6 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 3208.48% in 2025 and soared 144.11% in 2026, its largest moves.
• Tracing HNGE's EBITDA over 3 years: stood at $20.9 million in 2024, then surged by 30.35% to $27.3 million in 2025, then advanced by 17.66% to $32.1 million in 2026.
• Business Quant data shows HNGE's EBITDA at $32.1 million in Q1 2026, $27.3 million in Q4 2025, and -$6.1 million in Q3 2025.